Pfizer (PFE) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
Insiders put their own money in: $3.0M of open-market buys against $135K of sales. See how similar setups did below.
Past insider buys here: 3 of 3 beat the S&P 500 over the next 90 days (small sample). See each one ↓
Label: Strong buying · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Feb 2, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Purchase Albert Bourla, CEO, Chair bought 38,000 shares at $26.34 ($1.0M).
- Trade date
- Aug 12, 2026
- Disclosed to the SEC
- Aug 12, 2026
- Type
- Open-market purchase (code P)
Read the original SEC filing ↗All PFE insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
PFE insider transactions (Form 4)
Open-market purchases and sales. 28 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 12SEC | Albert BourlaCEO, ChairFirst buy | Buy | 38,000429,173 held (+10%) | $26.34 | $1.0M | +5.0% | — |
| Aug 6SEC | Jennifer B. DamicoSvp & Controller | Sell | 3,27828,611 held (−10%) | $25.40 | $83K | +8.8% | — |
| Aug 5SEC | Ronald E. BlaylockDirectorStake +142% | Buy | 39,23166,938 held (+142%) | $25.46 | $999K | +8.6% | — |
| Aug 5SEC | Mortimer J. BuckleyDirectorFirst buyNew positionPast buys 0/2 beat S&P | Buy | 37,632new position | $25.52 | $960K | +8.3% | 50 |
| Jun 10SEC | Jennifer B. DamicoSvp & Controller | Sell | 2,00031,397 held (−6%) | $25.70 | $51K | +7.6% | — |
Similar past setups: not applicable. There aren't enough comparable past cases for PFE's latest buying to report odds. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with PFE in the Research Lab
Pre-set to PFE's latest insider buy of $10K or more (Aug 12, 2026: Albert Bourla, Mortimer J. Buckley, Ronald E. Blaylock, $3.0M). Tap to change anything.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
- After PFE's buys7, 30 and 90 days later, losses included
- Find buys like this"3 insiders bought within 14 days over $1M after a rally in the last 12 months"
- Compare PFE vs KODInsider buying and selling side by side
- PFE's board links3 companies share insiders with PFE
- Play Insider Call5 real buys a day: guess which beat the market
Share price and insider trades
Pfizer insider trading at a glance (Nov 20, 2026): in the past 12 months, 3 insiders bought $3.0M and 1 sold $135K of PFE stock on the open market, including a cluster buy that began Aug 5, 2026; P/E 41.3 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
PFE insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $3.0M | 3 | $83K | 1 |
| Q2 2026 | — | 0 | $51K | 1 |
Valuation, profit and volume
Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 3 Pfizer insiders reported open-market purchases totaling $3.0M, while 1 insider reported sales totaling $135K. The most recent cluster buy began on Aug 5, 2026, when 3 insiders bought a combined $3.0M. Among insiders with enough purchase history to measure, Mortimer J. Buckley (Director) has the highest Insider Score at 50. 0 of 2 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
PFE earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Nov 3, 2026 | +3.7% | None | +0.4%S&P +2.0% | pending |
| Aug 4, 2026 | +1.7% | None | +3.1%S&P +1.6% | +10.2% |
| May 5, 2026 | -4.6% | None | +0.9%S&P +2.2% | -0.2% |
| Feb 3, 2026 | +5.7% | None | +0.5%S&P -1.3% | +1.0% |
| Nov 4, 2025 | +0.6% | None | -0.2%S&P -0.8% | +7.6% |
| Aug 5, 2025 | -2.2% | None | +1.7%S&P +0.3% | +4.0% |
| Apr 29, 2025 | +5.2% | None | +5.9%S&P +0.7% | -1.9% |
| Feb 4, 2025 | +1.3% | None | +0.9%S&P +1.1% | +1.1% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
PFE news sentiment trend
Weekly headline tone (positive minus negative headlines) over 13 weeks. Green dots mark weeks with insider buying.
Tone is scored from headline wording only. It describes the news, not where the stock is going.
PFE short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded PFE
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Michael A. RulliHouse · R-OH | Sold $1,001 - $15,000 | Nov 26, 2024 | Aug 7, 2026 | +21.0% |
| Thomas H TubervilleSenate | Sold $15,001 - $50,000 | May 3, 2024 | Aug 5, 2026 | +17.2% |
| Alan ArmstrongSenate | Sold $50,001 - $100,000 | Mar 24, 2026 | Jul 21, 2026 | +6.1% |
| Thomas H TubervilleSenate | Sold $15,001 - $50,000 | Jun 8, 2026 | Jul 16, 2026 | +9.8% |
| Gilbert Ray Cisneros, Jr.House · D-CA | Sold $1,001 - $15,000 | Mar 13, 2026 | Apr 7, 2026 | +7.6% |
| Gilbert Ray Cisneros, Jr.House · D-CA | Bought $1,001 - $15,000 | Feb 10, 2026 | Mar 9, 2026 | +3.6% |
| J. French HillHouse · R-AR | Sold $100,001 - $250,000 | Dec 31, 2025 | Jan 23, 2026 | +16.8% |
| Julia LetlowHouse · R-LA | Bought $1,001 - $15,000 | Jun 17, 2025 | Jan 13, 2026 | +25.4% |
| Gilbert Ray Cisneros, Jr.House · D-CA | Sold $1,001 - $15,000 | Dec 19, 2025 | Jan 12, 2026 | +15.4% |
| Gilbert Ray Cisneros, Jr.House · D-CA | Bought $1,001 - $15,000 | Nov 18, 2025 | Dec 15, 2025 | +14.2% |
| Lisa C. McClainHouse · R-MI | Sold $1,001 - $15,000 | Aug 4, 2025 | Sep 12, 2025 | +25.7% |
PFE stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
- Positive Pfizer Is Down 34 % Over the Last 5 Years . Here Why Its 6 % Dividend Yield Might Finally Be Worth the Risk . · aol.com
- News Oxford vaccine trial aims to prevent newborn infections · witneygazette.co.uk
- News Florida Attorney General sues Pfizer and CEO over COVID - 19 vaccine claims · freerepublic.com
- News AbbVie vs . Bristol Myers Squibb : Which Healthcare Stock Is a Better Buy in 2026 ? · fool.com
- Positive Kevin Warsh Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More Attractive · fool.com
- Positive Global Liver Metastases Treatment Market Overview : Prospects for Growth and Investment Opportunities Through 2035 · whatech.com
- Positive 2026 Analysis of the Lower Respiratory Tract Therapeutics Market : Strategic Insights and Projected Growth Trends · whatech.com
- News Policy Trump Medicare drug pricing model may apply to only four companies after exemptions · wabx.net
- 8-K Earnings release
- 8-K Investor disclosure
- 8-K Executive or board change
What happened after PFE insiders bought
Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.
| Filed | Insider | Bought | 7 days | 30 days | 90 days |
|---|---|---|---|---|---|
| Aug 12, 2026 | Albert BourlaCEO, Chair | $1.0M | +7.3%+7.8% vs S&P | +5.4%+6.4% vs S&P | +11.6%+14.3% vs S&P |
| Aug 5, 2026 | Mortimer J. BuckleyDirector | $960K | +1.9%+1.6% vs S&P | +10.2%+10.2% vs S&P | +14.6%+16.3% vs S&P |
| Aug 5, 2026 | Ronald E. BlaylockDirector | $999K | +1.9%+1.6% vs S&P | +10.2%+10.2% vs S&P | +14.6%+16.3% vs S&P |
Insiders at Pfizer
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Albert BourlaCEO, Chair | $1.0M | — | Aug 12, 2026 | — | — |
| Ronald E. BlaylockDirector | $999K | — | Aug 5, 2026 | — | — |
| Mortimer J. BuckleyDirector | $960K | — | Aug 5, 2026 | 0 of 2 | 50 |
| Jennifer B. DamicoSvp & Controller | — | $135K | Aug 6, 2026 | — | — |
| Douglas M. LanklerPresident | — | — | Feb 27, 2026 | — | — |
| Lidia FonsecaPresident | — | — | Feb 27, 2026 | — | — |
| Payal SahniPresident | — | — | Feb 27, 2026 | — | — |
| Michael McDermottPresident | — | — | Feb 27, 2026 | — | — |
| Christoffel BoshoffPresident | — | — | Feb 27, 2026 | — | — |
Board links: companies that share insiders with PFE
Directors and executives who filed Form 4s for PFE and another company in the last 12 months.
- BABoeing Mortimer J. Buckley Director here · Director at BA · latest filing Nov 3, 2026
- MDTMedtronic Lidia Fonseca President here · Director at MDT · latest filing Apr 29, 2026
- WRBW. R. Berkley Ronald E. Blaylock Director here · Director at WRB · latest filing Aug 5, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
PFE stock: common questions
Are Pfizer insiders buying PFE stock?
In the past 12 months, 3 insiders reported open-market purchases of PFE worth $3.0M. The latest was CEO, Chair Albert Bourla bought $1.0M of PFE at $26.34 — first open-market purchase in our records.
Are Pfizer insiders selling PFE stock?
1 insider reported sales worth $135K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is PFE's P/E ratio?
PFE trades at about 41.3 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is PFE's 52-week range?
Over the past year PFE has traded between $23.20 and $30.35. It last closed at $27.64 on Nov 19, 2026.